Elanco Animal Health beats Q4 revenue estimates, raises FY innovation revenue target

Elanco Animal Health Incorporated

24/02/2026 11:36

Overview

Animal health company's Q4 revenue rose 12%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Outlook

Elanco projects 2026 revenue of $4.95 bln to $5.02 bln

Company expects 2026 adjusted EBITDA of $955 mln to $985 mln

Elanco raises 2026 innovation revenue target to $1.15 bln

Result Drivers

NEW PRODUCTS - Revenue growth driven by new products like Credelio Quattro and Zenrelia, contributing to pet health sector

FARM ANIMAL SALES - Growth in farm animal revenue supported by Experior in cattle and strong poultry sales

INNOVATION PIPELINE - Approval of Befrena and strong innovation momentum cited as growth drivers

Company press release: ID:nPnbDd19Ra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$1.14 bln
$1.09 bln (12 Analysts)
Q4 Adjusted EPS
Beat
$0.13
$0.11 (14 Analysts)
Q4 EPS
-$0.56
Q4 Adjusted Net Income
Beat
$64 mln
$55.28 mln (12 Analysts)
Q4 Net Income
-$276 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Elanco Animal Health Inc is $27.00, about 9.1% above its February 23 closing price of $24.75

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)